Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
766.00
+10.00 (1.32%)
Apr 28, 2026, 1:30 PM CST
533.06%
Market Cap 48.93B
Revenue (ttm) 31.42M
Net Income (ttm) -423.94M
Shares Out 64.72M
EPS (ttm) -7.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 70,404
Average Volume 205,475
Open 756.00
Previous Close 756.00
Day's Range 756.00 - 786.00
52-Week Range 121.00 - 929.00
Beta 1.39
RSI 58.93
Earnings Date May 5, 2026

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6949
Full Company Profile

Financial Performance

In 2025, Pell Bio-Med Technology's revenue was 31.42 million, an increase of 60.07% compared to the previous year's 19.63 million. Losses were -423.94 million, 8.87% more than in 2024.

Financial Statements

News

There is no news available yet.